secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001213900-26-025432
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC
--------------------------------------------------------------------------------

- Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).
- Cash $197.9M as of Dec 31, 2025; expects funding into 2028 after $86.3M December offering.
- TARA-002 in BCG-Unresponsive NMIBC: 68.2% complete response at six months; no grade 3+ TRAEs.
- FDA granted TARA-002 Breakthrough Therapy and Fast Track designations for lymphatic malformations.
- Expects to complete BCG-Unresponsive cohort enrollment in 2H 2026; initiate ADVANCED-3 trial in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea0280404-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-025432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer